The International Society for Stem Cell Research (ISSCR) Launches Web Site Providing Information on Stem Cell Treatments


Deerfield, IL (PRWEB) June 8, 2010 ?

The International Society for Stem Cell Research (ISSCR) announced today that it has launched ?A Closer Look at Stem Cell Treatments? (http://www.closerlookatstemcells.org), a Web site to arm patients, their families and doctors with information they need to make decisions about stem cell treatments. The Web site was developed in response to the growing number of aggressive marketing campaigns on the Internet and elsewhere offering stem cell treatments. The ISSCR urges individuals to be cautious and to learn the facts before making any decision.

?Stem cells do hold tremendous promise for the treatment of many serious diseases. Yet there are organizations out there that are preying on patients? hopes, offering stem cell treatments ? often for large sums of money ? for conditions where the current science simply does not support its benefit or safety,? said Irving Weissman, MD, President of the ISSCR. ?We want to stress through this initiative that there are internationally accepted medical criteria for getting new medicines into clinics. Patients have a right to know if the clinic or treatment they are considering adheres to these criteria. We feel it is an obligation of the ISSCR to both a) alert patients and caregivers about clinics and other entities that are selling unproven ?stem cell? therapies, and b) help shepherd real stem cell advances from discovery to successful patient treatments as rapidly as possible. ?

Currently there are only a small number of stem cell treatments that have been shown to be beneficial in rigorous studies. These mostly pertain to diseases or conditions of the blood as well as skin grafts and corneal repair. The ISSCR is concerned that stem cell treatments are being marketed to patients worldwide for a variety of medical conditions, without having the mechanisms in place to ensure safety or likely benefit. Without these safeguards, patients may be put at risk.

A Closer Look at Stem Cell Treatments offers several tools for patients to evaluate a prospective clinic or treatment including a list of questions to ask about the treatment and providers as well as resources that explain fundamental scientific principles of stem cell biology and the implications for stem cell treatments. Ultimately, the Web site will list stem cell clinics and whether they do or do not provide the ISSCR with information showing that appropriate oversight and other patient protections are in place.

Visitors to http://www.closerlookatstemcells.org can submit, for review, a clinic or treatment they have seen advertised. The treatment providers will be asked to present evidence that a) a medical ethics committee is involved to protect patients? rights; and b) there is supervision by an official regulatory body such as the European Medicines Agency (EMA) or the U.S. Food and Drug Administration (FDA) for the trial or approved use of a treatment for specific diseases or conditions.

?We want patients to feel they have access to critical information they might otherwise not have, so they can make the best decision for their individual situation,? said Patrick Taylor, JD, Chair of the ISSCR Task Force on Unproven Stem Cell Treatments. “The key to ensuring that treatments are safe and effective is a well-established path from basic research to clinical care, through carefully constructed studies and independent review. The criteria selected by the task force are simple to apply, but of extraordinary power in promoting progress while protecting patients.”

The International Society for Stem Cell Research (ISSCR) is an independent, nonprofit organization established to promote and foster the exchange and dissemination of information and ideas relating to stem cells, to encourage the general field of research involving stem cells and to promote professional and public education in all areas of stem cell research and application.

###





More Stem Cell Food Press Releases

GeneCell International, LLC. – The First and Only Umbilical Cord Blood Processing and Cryopeservation Laboratory in Miami, Now Offers a New Stem Cell Banking Service ? Dental Pulp Stem Cells


Miami, Florida (Vocus/PRWEB) April 13, 2011

GeneCell International, a trusted provider in the processing and preservation of umbilical cord blood, announced today they are offering a new stem cell banking service, the banking of stem cells from dental pulp.

Dental pulp stem cells, found in the pulp chamber of teeth, are a relatively new discovery in the realm of adult stem cells, they have the ability to differentiate into numerous cell types including bone, muscle, nerve, cartilage and fat. ?Since these cells have the capability to differentiate into a variety of tissue types, they open up the door to potentially treat a variety of different diseases including heart attack, bone repair, neural degenerative disorders, like Parkinson?s disease,? said GeneCell International?s Director of Research and Laboratory Operations, Dr. Todd R. Flower.

Dental pulp stem cells hold the potential of possibly regenerating damaged tissues and organs in the body by stimulating organs to heal themselves. These cells may be one of the most promising cell-therapies in the future. In the past, extracted teeth and related tissue have been viewed as a medical waste and discarded, resulting in a loss of this potential life-saving resource. Now clients can save these cells so they are available to them in the future should they be necessary.

With more than a decade of knowledge and experience in the stem cell industry, GeneCell is uniquely poised to help parents in the US, Latin America and the Caribbean make informed decisions regarding the potential benefit on how dental pulp stem cells may help safeguard their families. ?Our new headquarters in Miami provides easily-accessible resources for parents looking to potentially protect their children, and patients looking for medical solutions to diseases that were once untreatable,? said GeneCell?s Operations Manager, Jose Cirino.

About Dental Pulp Stem Cell Preservation

Dental Pulp Stem Cell preservation is a process by which the pulp tissue is extracted from the tooth and is stored cryogenically in a specially-designated bank. Currently there are no clinical applications for these cells; however numerous research studies have indicated potential use in the enhancement of wound healing, bone regeneration, tooth regeneration, a potential cellular therapy option for Parkinson?s disease and Alzheimer?s disease, liver regeneration, and muscle regeneration. Dental pulp stem cell banking is regulated by the U.S. Food & Drug Administration.

About GeneCell International, LLC.

GeneCell International, LLC is a trusted provider of collection, processing and storage of dental pulp stem cells and umbilical cord blood from which stem cells can be extracted to treat a variety of diseases and disorders. GeneCell operates state of the art laboratories and storage facilities for the cord blood of thousands of clients, headquartered in Miami, Florida and with local offices in Central Florida, Texas, Connecticut, Massachusetts, Rhode Island, the Dominican Republic, Panama, and Venezuela. For more information and to learn more about dental pulp stem cell banking benefits and services, visit http://www.GeneCell.com.

###





Physician Group Opposes FDA’s Position on Adult Stem Cells


Broomfield, CO (PRWEB) March 26, 2009

The American Stem Cell Therapy Association (ASCTA) announced today the online publication of its mission statements and charter. The organization was formed in response to the Food and Drug Administration’s (FDA) recent position that the adult stem cells found in everyone’s body are drugs, a position the ASCTA opposes. This physician organization is establishing laboratory guidelines that will allow doctors to bring adult stem cell therapy to their patients more quickly. These guidelines will be similar to those used by fertility specialists in In-Vitro Fertilization (IVF) labs, where many of the same cell culture techniques are used.

“Many patients are dying or suffering daily with incurable diseases or problems that require major surgery. These patients should have access to basic adult stem cell therapy now.” stated Christopher J. Centeno, M.D, an ASCTA physician member. “ASCTA is establishing guidelines which will allow the safe use of the patient’s own adult stem cells under the supervision of doctors.” continued Centeno. Another ASCTA physician member, Frank Falco, M.D. stated, “The FDA’s position against someone using their own stem cells is taking it too far. We are talking about a person using their own tissue to treat a degenerative disorder or process safely without the use of medications or surgery. Although we agree that oversight and standards are necessary, this should be provided through a physician organization such as ASCTA rather than by a government agency.”

Adult stem cells are different than embryonic stem cells. Adult stem cells are found in the patient’s body in various tissues. In order to obtain enough stem cells for treatment, they often need to be cultured, similar to today’s fertility treatments. Adult stem cells have undergone much more research than embryonic stem cells and therefore are closer to real world treatments. These adult stem cells are taken from the patient’s own body (autologous) and ACSTA believes that they are therefore the safest for use in treating patients. “While the Obama administration seems to have opened the embryonic stem cell door, their FDA seems to want to slam the adult stem cell door shut”, stated Dr. Centeno.

About the American Stem Cell Therapy Association

The ASCTA is a physician group comprised of various medical and surgical specialties whose goal is to bring safe stem cell therapy to patients by establishing laboratory and clinical guidelines. Christopher J. Centeno, M.D. is a board certified pain management specialist in Colorado who utilizes The Regenexx Procedure, an innovative adult stem cell therapy that helps patients avoid the need for more invasive orthopedic surgery. Dr. Centeno has published numerous medical research papers on the clinical application of adult mesenchymal stem cells. Frank Falco, M.D. is a board certified pain management physician and program director of the Temple University Hospital pain medicine fellowship located in Philadelphia, Pennsylvania who implements minimally invasive techniques for treatment of painful conditions including degenerative spine disorders. For more information, visit http://www.stemcelldocs.org.

Press contact:

Holly Hamann

720-290-0007

###